Re2O and Re2O Fine in Daegu: how do they differ? — Same material, different particles
Lately more people say at consultation, “Please do Re2O Fine, not Re2O.” With ‘Fine’ in the name it sounds like a better new product, but I don’t explain it that way. The two products share the same material and differ in particle size and the amount per vial. So it is right to ask “which spot does it suit” rather than “which is better.” This piece covers the differences the manufacturer has published, how far human data goes, and how I divide their use. No prices or photos.
The short answer
Re2O and Re2O Fine are both finely processed material from human dermis with the cells removed (hADM). What differs is particle size and amount. By the manufacturer’s figures, Re2O averages about 100 µm · 150 mg and Re2O Fine about 50 µm · 50 mg. Fine, with smaller particles, is aimed at being placed evenly in thin skin. But we found no trial comparing the two side by side in people, and the randomised human trial that exists finished before Fine came out. Miso Clinic in Daegu (4F Bombom Building, 125 Dongdeok-ro, Jung-gu, Daegu, +82-53-428-2700) uses Fine for thin-skinned areas and Re2O for broad areas, deciding at consultation by area and skin thickness.
Are Re2O and Re2O Fine the same product?
The material is the same. Both are in the ‘Elravie Re2O’ line made by L&C Bio, made by removing cells from human dermis and turning the remaining structure (extracellular matrix such as collagen · elastin) into injectable particles. So both are managed as human tissue rather than medicines, and their history from donation to distribution is recorded.
What changed is how finely the particles are made and how much is in one vial. I explain it as close to the difference between grinding the same flour coarsely or finely.
In numbers, they differ like this
| Category | Re2O | Re2O Fine | Re2O V |
|---|---|---|---|
| Average particle size | About 100 µm | About 50 µm | More than twice Re2O |
| One vial | 150 mg | 50 mg | 300 mg |
| Use stated by the manufacturer | Skin restoration · regeneration, broad areas | Precisely in thin skin, evenly within the dermis | Structural support in deep layers |
| Released | November 2024 | December 2025 | Announced October 2026 (release date not set) |
The figures in the table all come from manufacturer announcements and press coverage. Particle size is an ‘average of about,” so in reality large and small particles are mixed. And 50 mg and 150 mg are “the amount in one vial,” not “the amount injected in one treatment.” There is still no published standard for how much goes in at once.
Re2O V was only announced this month, so this piece just marks its place. Its particles are larger, aimed at supporting layers deeper than the dermis, so its role differs again from Re2O · Fine.
What changes when particles are smaller?
In principle there are three things. Let me say first that these are expectations derived from particle size, not results confirmed by trials.
- It passes through a fine needle more easily. With larger particles, needle gauge or dilution must be matched so the needle doesn’t clog. Small particles carry less of that burden.
- It is easier to lay evenly in thin dermis. In spots with thin dermis like around the eyes, large particles gathering in one place can be felt or show through. This is why the manufacturer describes Fine as “even distribution in thin skin.”
- There is less per vial. It is configured for precisely treating narrow spots rather than filling the whole broad face.
Conversely, I found no basis for “smaller particles work better” or “last longer.” There is no data yet measuring in people how long small particles stay in the dermis, or how their collagen response compares with large particles.
How far does human data go?
There is currently one randomised human trial in the Re2O line. It is a double-blind trial in 20 people with particulate hADM on one side of the face and hyaluronic acid on the other, followed for 20 weeks; indicators such as skin density · elasticity · wrinkle depth · pores improved more on the hADM side. There were no serious adverse events.
But this trial started in November 2024 and finished in May 2025. Re2O Fine came out in December 2025, so this trial’s results were not obtained with Fine.
As of 15 October 2026, I found on PubMed no human study with Re2O Fine alone, and no trial comparing Re2O and Fine side by side in people. That is “not found,” not “doesn’t exist.” So when speaking of Fine’s effect, we are borrowing trial results for the same material, and whether they can be carried over as is, given the change in particle size, is still an open question.
This is how I divide their use
Since the material is the same, the criterion for choosing is not a ranking of effect but the spot.
| Situation | Look at first | Reason |
|---|---|---|
| Thin-skinned areas such as around the eyes | Re2O Fine | To place small particles evenly in thin dermis |
| Texture · firmness of the cheeks · broad facial areas | Re2O | The amount per vial and particle size suit broad areas |
| Deeply hollow cheeks · temples | Neither first | We look first at dissolvable hyaluronic acid filler |
| Facial sagging is the concern | Neither first | A booster won’t lift sagging. Lifting comes first |
Sometimes both products are used on one face, divided by spot. I don’t fix the tool either. Depending on your needs, I choose between a cannula and a needle (hand injection). Needles and cannulas are written up separately in Re2O by needle and cannula.
What I check when you say “please do Fine”
- Which spot is the concern? For the eye area · thin skin, Fine may suit; for whole-cheek texture, Re2O may suit.
- How thin is the skin? Even around the eyes, dermal thickness differs from person to person. We decide by feeling it.
- Is hollowing or sagging mixed in? If so, filler or lifting may come before choosing the type of booster.
- Do you want to check the product yourself? Re2O and Fine differ in box labelling and volume. Before treatment we show you the box, the label and the opening.
Not established
- A human trial with Re2O Fine alone
- A trial comparing Re2O and Re2O Fine side by side in people
- Data measuring whether time in the dermis differs by particle size
- A published standard for the amount injected in one treatment
- Re2O V’s release date and human data
The manufacturer announced in August 2026 that it had formed an advisory committee to set standards for application areas and methods of use. When that is published, I will revise this piece.
Re2O · Re2O Fine: frequently asked questions
How do Re2O and Re2O Fine differ?
The material is the same human dermis-derived hADM; particle size and amount per vial differ. By the manufacturer’s figures, Re2O averages about 100 µm · 150 mg and Re2O Fine about 50 µm · 50 mg.
Is Re2O Fine the better product?
It is not so much a better product as one matched to a different spot. We found no trial comparing the two side by side in people. Fine is aimed at being placed evenly in thin skin.
Where does Re2O Fine suit?
The manufacturer explains it was made to spread evenly within the dermis in thin skin. Miso Clinic looks at Fine first for thin-skinned areas such as around the eyes.
Has Re2O Fine’s effect been confirmed too?
The randomised human trial in the Re2O line (20-person split face) finished before Fine came out. As of October 2026 we found no human study with Fine alone.
What is Re2O V?
A product in the same line announced in October 2026, with particles more than twice Re2O’s and 300 mg per vial. It is aimed at supporting structure in deep layers. The release date has not been announced.
Can Re2O and Re2O Fine be used together?
Sometimes they are used together on one face, divided by spot. As the same material, it means dividing by area rather than layering.
Where can I get a Re2O consultation in Daegu?
Miso Clinic in Daegu is at 4F Bombom Building, 125 Dongdeok-ro, Jung-gu, Daegu, in front of Exit 1 of Kyungpook National University Hospital Station. +82-53-428-2700; weekdays 11:00–19:00 · Saturday 10:00–16:00; closed Sundays · public holidays.
Clinical columns to read next
- Juvelook complete review — ingredients · six products · research · how to choose
- The Juvelook line-up spec sheet on one page
- Re2O (hADM) product reference
- Re2O (hADM) in Daegu: what goes in and what has been observed
- Re2O by needle and cannula: what has been confirmed
- Re2O density and the dermal layer: why embossing happens
- CellREDM and Re2O in Daegu: both hADM, so what differs?
- Re2O and Rejuran put in different things
- Re2O in Daegu: five things worth checking before consultation
Product reference
Product reference: Re2O — human dermis-derived hADM booster
Clinic
This column was written and reviewed by Lee Chi-Hak, MD, medical director of Miso Clinic in Daegu. The treatment criteria and injection design are written exactly as we actually use them.
| Medical Director | Lee Chi-Hak, MD |
|---|---|
| Address | 4F Bombom Building, 125 Dongdeok-ro, Jung-gu, Daegu (Exit 1, Kyungpook National University Hospital Station) · tower parking in the building |
| Phone | 053-428-2700 |
| KakaoTalk consultation | Miso Clinic Daegu channel |
| KakaoTalk channel | Add the channel |
| Opening hours | Weekdays 11:00–19:00 (lunch 13:00–14:00) / Saturday 10:00–16:00 (no lunch break) / Closed Sundays and public holidays |
| Clinical column | See all columns |
| Reference library | All booster and lifting device references |
References
- Re2O line-up figures — Pharm Edaily, “‘Sold-out’ Re2O line-up expands,” 2025-12. Re2O average about 100 µm · 150 mg (released November 2024), Re2O Fine average about 50 µm · 50 mg.
- Re2O Fine launch — Pharm Edaily, “L&C Bio launches more refined ECM-based skin booster ‘Re2O Fine’,” 2025-12-05. Manufacturer’s explanation: smaller volume than existing Re2O · finer particles (average about 50 µm), aimed at even distribution within the dermis in thin skin.
- Re2O V announced — Seoul Economic Daily, “Particles twice as large… L&C Bio · Humedix unveil ‘Re2O V’,” 2026-10-08. Particles more than twice existing Re2O, 300 mg, aimed at structural support in deep layers. No release date in the article.
- Human trial in the Re2O line — Lee YI et al., Int J Mol Sci 2026;27(5):2193, PMID 41828422, DOI 10.3390/ijms27052193. Randomised · double-blind split face, 20 people, particulate hADM on one side · hyaluronic acid on the other, 20 weeks. Registry NCT07155278 (started 2024-11 · completed 2025-05, three intradermal injections a month apart). A trial that finished before Re2O Fine was released (2025-12).
- Manufacturer advisory committee — Dailypharm, “L&C Bio launches Re2O advisory committee,” 2026-08-24. Announcement that it would set out application areas · injection sites · standard methods of use.
- Not confirmed — a human trial of Re2O Fine alone, a head-to-head trial of Re2O vs Fine, data on residence time by particle size, a standard amount per injection (as of PubMed · press on 2026-10-15).
- Miso Clinic’s approach — Re2O Fine for thin-skinned areas, Re2O for broad areas, dissolvable hyaluronic acid filler first for deep hollows, lifting first for sagging, cannula and needle chosen as needed. The source of sentences written as “I · we” in this column.
- Medical advertising law — Korean Medical Service Act Article 56(2) (no treatment testimonials · comparison · superlatives), Article 27(3) (no inducing patients for profit). This is why this column carries no reviews · before-and-after photos · prices.
Everything in this column is general information and does not replace medical diagnosis or treatment. Effects and side effects vary with individual skin condition, age and underlying illness, and the same result is not guaranteed for everyone. Any decision to proceed should be made in an in-person consultation with a physician.